DK1058562T3 - Præparater og fremgangsmåder til behandling af tumorer - Google Patents
Præparater og fremgangsmåder til behandling af tumorerInfo
- Publication number
- DK1058562T3 DK1058562T3 DK99908641T DK99908641T DK1058562T3 DK 1058562 T3 DK1058562 T3 DK 1058562T3 DK 99908641 T DK99908641 T DK 99908641T DK 99908641 T DK99908641 T DK 99908641T DK 1058562 T3 DK1058562 T3 DK 1058562T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- protein
- erb
- individual
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7678898P | 1998-03-04 | 1998-03-04 | |
US09/111,681 US6417168B1 (en) | 1998-03-04 | 1998-07-08 | Compositions and methods of treating tumors |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1058562T3 true DK1058562T3 (da) | 2006-11-13 |
Family
ID=26758479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99908641T DK1058562T3 (da) | 1998-03-04 | 1999-03-04 | Præparater og fremgangsmåder til behandling af tumorer |
Country Status (13)
Country | Link |
---|---|
US (8) | US6417168B1 (da) |
EP (2) | EP1058562B1 (da) |
JP (2) | JP2002505309A (da) |
AT (1) | ATE334702T1 (da) |
AU (1) | AU757237C (da) |
CA (1) | CA2322592A1 (da) |
CY (1) | CY1105475T1 (da) |
DE (1) | DE69932600T2 (da) |
DK (1) | DK1058562T3 (da) |
ES (2) | ES2270586T3 (da) |
HK (1) | HK1225997A1 (da) |
PT (1) | PT1058562E (da) |
WO (1) | WO1999044645A1 (da) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030108545A1 (en) * | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
ATE278794T1 (de) | 1995-06-15 | 2004-10-15 | Crucell Holland Bv | Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie |
EP1745799B1 (en) | 1998-03-04 | 2015-09-02 | The Trustees of The University of Pennsylvania | Compositions and methods of treating tumors |
US6417168B1 (en) | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
US20030224001A1 (en) * | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
US6929946B1 (en) * | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
US7625859B1 (en) * | 2000-02-16 | 2009-12-01 | Oregon Health & Science University | HER-2 binding antagonists |
US7396810B1 (en) * | 2000-08-14 | 2008-07-08 | Oregon Health Sciences University | Compositions and methods for treating cancer by modulating HER-2 and EGF receptors |
US7393823B1 (en) | 1999-01-20 | 2008-07-01 | Oregon Health And Science University | HER-2 binding antagonists |
IL146480A0 (en) * | 1999-05-14 | 2002-07-25 | Imclone Systems Inc | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
US20050232900A1 (en) * | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6913922B1 (en) * | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US20030086924A1 (en) * | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
CA2383493C (en) * | 1999-06-25 | 2010-08-10 | Genentech, Inc. | Treating prostate cancer with anti-erbb2 antibodies |
US20040013667A1 (en) * | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
WO2001083781A2 (en) * | 2000-04-28 | 2001-11-08 | Millennium Pharmaceuticals, Inc. | 14094, a novel human trypsin family member and uses thereof |
AU2001295002B2 (en) * | 2000-08-09 | 2007-05-31 | Imclone Systems Incorporated | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
US20070286845A1 (en) * | 2000-11-17 | 2007-12-13 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
US8039261B2 (en) * | 2000-11-17 | 2011-10-18 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
WO2003033514A1 (en) | 2001-10-19 | 2003-04-24 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
US20050239738A1 (en) * | 2000-11-17 | 2005-10-27 | Rupert Schmidt-Ullrich | Genetic inhibition of epidermal growth factor receptor function and carcinoma cell radiosensitization |
US8071740B2 (en) * | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
US20100282634A1 (en) * | 2000-11-17 | 2010-11-11 | Dror Harats | Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis |
US20080008704A1 (en) * | 2001-03-16 | 2008-01-10 | Mark Rubin | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies |
WO2002081649A2 (en) * | 2001-04-06 | 2002-10-17 | The Trustees Of The University Of Pennsylvania | ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
US7589180B2 (en) | 2001-05-11 | 2009-09-15 | Abbott Laboratories Inc. | Specific binding proteins and uses thereof |
US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
WO2003012072A2 (en) * | 2001-08-03 | 2003-02-13 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
AU2002365258A1 (en) * | 2001-10-12 | 2003-09-02 | University Of Vermont And State Agricultural College | Binding peptides specific for the extracellular domain of erbb2 and uses therefor |
WO2003045309A2 (en) * | 2001-11-21 | 2003-06-05 | The Trustees Of The University Of Pennsylvania | Peptides, peptide compositions,and methods of use in binding p 185 |
ATE447037T1 (de) * | 2002-04-25 | 2009-11-15 | Crucell Holland Bv | Mittel und verfahren zur herstellung von adenovirusvektoren |
US20030202973A1 (en) * | 2002-04-29 | 2003-10-30 | Dr. George Pieczenik | Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists |
US20040229380A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
US20040229294A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
US7402397B2 (en) | 2002-05-21 | 2008-07-22 | Monogram Biosciences, Inc. | Detecting and profiling molecular complexes |
EP1513543B1 (en) | 2002-05-23 | 2010-10-06 | The Trustees of The University of Pennsylvania | Fas peptide mimetics and uses thereof |
WO2004005320A2 (en) | 2002-07-03 | 2004-01-15 | The Curators Of The University Of Missouri | ErbB-2 RECEPTOR TARGETING PEPTIDE |
DK2263691T3 (da) * | 2002-07-15 | 2012-10-22 | Hoffmann La Roche | Behandling af cancer med det rekombinante humaniserede monoklonale anti-ErbB2-antistof 2C4 (rhuMAb-2C4) |
EP1572972A4 (en) * | 2002-11-21 | 2007-11-21 | Genentech Inc | THERAPY OF NON-MALIGNER DISEASES OR DISORDER WITH ANTI-ERBB2 ANTIBODIES |
EP1622941A2 (en) * | 2003-03-20 | 2006-02-08 | ImClone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
CA2521082A1 (en) * | 2003-04-01 | 2004-10-28 | Monogram Biosciences, Inc. | Surface receptor complexes as biomarkers |
EP1681983A4 (en) * | 2003-10-14 | 2008-12-10 | Monogram Biosciences Inc | RECEPTOR TYROSINE KINASE SIGNAL PATH ANALYSIS FOR DIAGNOSIS AND THERAPY |
PL1735348T3 (pl) * | 2004-03-19 | 2012-11-30 | Imclone Llc | Ludzkie przeciwciało przeciwko receptorowi naskórkowego czynnika wzrostu |
WO2006009694A2 (en) * | 2004-06-14 | 2006-01-26 | Imclone Sysetms Incorporated | Crystal of egfr extracellular domain and cetuximab fab fragment and uses thereof |
EP1807106A2 (en) * | 2004-10-05 | 2007-07-18 | Oregon Health and Science University | Compositions and methods for treating disease |
US20070009972A1 (en) * | 2005-02-16 | 2007-01-11 | Ginger Chao | Epidermal growth factor receptor polypeptides and antibodies |
CN103251946A (zh) | 2005-02-23 | 2013-08-21 | 健泰科生物技术公司 | 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活 |
WO2006096861A2 (en) * | 2005-03-08 | 2006-09-14 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs) |
US8465732B2 (en) | 2007-01-19 | 2013-06-18 | Cornell Research Foundation, Inc. | Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof |
MX338185B (es) | 2007-01-25 | 2016-04-05 | Dana Farber Cancer Inst Inc | Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante. |
SI2129396T1 (sl) | 2007-02-16 | 2013-12-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in njihove uporabe |
SI2132573T1 (sl) | 2007-03-02 | 2014-07-31 | Genentech, Inc. | Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3 |
WO2008115404A1 (en) | 2007-03-15 | 2008-09-25 | Ludwing Institute For Cancer Research | Treatment method using egfr antibodies and src inhibitors and related formulations |
ES2583377T3 (es) | 2007-06-08 | 2016-09-20 | Genentech, Inc. | Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2 |
EP2188311B1 (en) | 2007-08-14 | 2016-10-05 | Ludwig Institute for Cancer Research Ltd. | Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof |
AU2008312580A1 (en) * | 2007-10-16 | 2009-04-23 | Symphogen A/S | Compositions comprising optimized Her1 and Her3 multimers and methods of use thereof |
US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
CN108864285A (zh) | 2008-01-03 | 2018-11-23 | 斯克里普斯研究院 | 通过模块识别结构域的抗体靶向 |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
EA022884B1 (ru) | 2008-08-15 | 2016-03-31 | Мерримак Фармасьютикалз, Инк. | СПОСОБ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ С ИСПОЛЬЗОВАНИЕМ АНТИ-ErbB3 АНТИТЕЛА |
WO2010051502A2 (en) * | 2008-10-31 | 2010-05-06 | Biogen Idec Ma Inc. | Light targeting molecules and uses thereof |
SG174378A1 (en) | 2009-03-20 | 2011-10-28 | Genentech Inc | Bispecific anti-her antibodies |
DK2544680T3 (da) | 2010-03-11 | 2015-04-27 | Merrimack Pharmaceuticals Inc | Anvendelse af erbb3-hæmmere i behandlingen af triple-negativ brystcancer |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
JP6082344B2 (ja) | 2010-05-27 | 2017-02-15 | ゲンマブ エー/エス | Her2エピトープに対するモノクローナル抗体 |
CN107253992B (zh) | 2010-05-27 | 2022-03-11 | 根马布股份公司 | 针对her2的单克隆抗体 |
WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
US9427458B2 (en) * | 2010-07-22 | 2016-08-30 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas, Conicet | Methods for inhibiting cancer cell proliferation |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
CA2832389A1 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
WO2012162561A2 (en) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
BR112014011886A2 (pt) | 2011-11-17 | 2017-05-16 | Bayer Medical Care Inc | métodos e técnicas para coleta, relatório e gestão de informações sobre procedimentos médicos diagnósticos |
CN104093743B (zh) | 2011-11-23 | 2018-04-24 | 医学免疫有限责任公司 | 特异于her3的结合分子及其用途 |
RU2014126098A (ru) | 2011-11-30 | 2016-01-27 | Дженентек, Инк. | МУТАЦИИ ErbB3 ПРИ РАКЕ |
IN2014KN01772A (da) * | 2012-02-23 | 2015-10-23 | U3 Pharma Gmbh | |
WO2013148315A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
CN105163762B (zh) | 2013-03-14 | 2019-06-25 | 乔治敦大学 | 对神经毒剂的暴露的治疗 |
US10150800B2 (en) | 2013-03-15 | 2018-12-11 | Zyngenia, Inc. | EGFR-binding modular recognition domains |
US11446516B2 (en) | 2013-08-09 | 2022-09-20 | The Trustees Of The University Of Pennsylvania | Methods of increasing response to cancer radiation therapy |
EP4137519A1 (en) | 2013-08-09 | 2023-02-22 | The Trustees Of The University Of Pennsylvania | Fusion protein comprising ifn-gamma and anti-erbb antibody for the treatment of cancers |
WO2015048008A2 (en) | 2013-09-24 | 2015-04-02 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
WO2015157634A1 (en) | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
AU2015279552B2 (en) * | 2014-06-27 | 2021-01-21 | Angiocrine Bioscience, Inc. | Neural cells expressing adenovirus E4ORF1, and methods of making and using the same |
EP3283111A4 (en) * | 2015-04-17 | 2019-04-17 | Celldex Therapeutics, Inc. | BIOMARKERS RELATED TO TREATMENT OF CANCER WITH HER3 AND EGFR INHIBITORS |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
EP3615695A1 (en) | 2017-04-24 | 2020-03-04 | Genentech, Inc. | Erbb2/her2 mutations in the transmebrane or juxtamembrane domain |
US11430558B2 (en) | 2017-07-07 | 2022-08-30 | Bayer Healthcare Llc | System, method, and computer program product for peer exchange of data between injection systems |
WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
CA3209779A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
WO2023039613A2 (en) * | 2021-09-13 | 2023-03-16 | The Board Of Regents Of The University Of Texas System | Lilrb2-specific monoclonal antibodies and methods of their use |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US600377A (en) * | 1898-03-08 | Spring saddle-post | ||
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4241046A (en) | 1978-11-30 | 1980-12-23 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
DE3481172D1 (de) * | 1983-10-26 | 1990-03-08 | Sheldon B Greer | Verfahren und materialien zum empfindlichmachen eines neoplastischen gewebes vor strahlung. |
US5637677A (en) * | 1987-07-16 | 1997-06-10 | The Trustees Of The University Of Pennsylvania | Biologically active compounds and methods of constructing and using the same |
US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
US5470571A (en) | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
US5200178A (en) | 1988-02-26 | 1993-04-06 | The General Hospital Corporation | Method for tumor detection |
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5705157A (en) | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
US5464751A (en) | 1990-04-06 | 1995-11-07 | Trustees Of The University Of Pennsylvania | Ligand for the neu gene product |
US5367060A (en) | 1991-05-24 | 1994-11-22 | Genentech, Inc. | Structure, production and use of heregulin |
WO1993014781A1 (en) | 1992-01-24 | 1993-08-05 | The Regents Of The University Of California | Novel peptides and method for altering the activity of allosteric proteins |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
PT616812E (pt) | 1993-03-24 | 2000-04-28 | Berlex Biosciences | Combinacao de compostos anti-hormonais e moleculas de ligacao no tratamento do cancro |
AU6527894A (en) * | 1993-03-30 | 1994-10-24 | Trustees Of The University Of Pennsylvania, The | Prevention of tumors with monoclonal antibodies against (neu) |
US6733752B1 (en) * | 1994-03-30 | 2004-05-11 | The Trustees Of The University Of Pennsylvania | Prevention of tumors with monoclonal antibodies against neu |
GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
WO1995024190A2 (en) * | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
US5837523A (en) | 1994-05-05 | 1998-11-17 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
US6100377A (en) | 1994-06-10 | 2000-08-08 | The Trustees Of The University Of Pennsylvania | Constrained peptides |
US5707618A (en) | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
DE69533187T2 (de) | 1995-04-28 | 2005-07-07 | Hewlett-Packard Development Co., L.P., Houston | Elektrooptische Anzeigevorrichtung |
US5663144A (en) | 1995-05-03 | 1997-09-02 | The Trustees Of The University Of Pennsylvania | Compounds that bind to p185 and methods of using the same |
US5756283A (en) | 1995-06-05 | 1998-05-26 | The Trustees Of The University Of Pennsylvania | Method for improved production of recombinant adeno-associated viruses for gene therapy |
US6281010B1 (en) | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
CN1214044C (zh) * | 1996-03-27 | 2005-08-10 | 基因技术股份有限公司 | ErbB3抗体 |
WO1998002540A1 (en) | 1996-07-12 | 1998-01-22 | Genentech, Inc. | Chimeric heteromultimer adhesins |
CA2269204C (en) | 1996-10-18 | 2012-01-24 | Genentech, Inc. | Anti-erbb2 antibodies |
WO1998018489A1 (en) | 1996-10-30 | 1998-05-07 | The Uab Research Foundation | Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies |
US6074640A (en) * | 1997-10-30 | 2000-06-13 | Uab Research Foundation | Enhancement of tumor cell radiosensitivity using single chain intracellular antibodies |
US6027892A (en) * | 1996-12-30 | 2000-02-22 | Chang Esther H | Compositions and methods for reducing radiation and drug resistance in cells |
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US6417168B1 (en) | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
EP1745799B1 (en) | 1998-03-04 | 2015-09-02 | The Trustees of The University of Pennsylvania | Compositions and methods of treating tumors |
JP2002515511A (ja) | 1998-05-15 | 2002-05-28 | イムクローン システムズ インコーポレイティド | 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療 |
DE10124566A1 (de) | 2001-05-15 | 2002-11-21 | Zeiss Carl | Optisches Abbildungssystem mit Polarisationsmitteln und Quarzkristallplatte hierfür |
US6828474B2 (en) | 2002-03-06 | 2004-12-07 | National Starch & Chemical Investment Holding Corporation | Method of grain production for heterozygous waxy sugary-2 maize |
WO2010129579A2 (en) | 2009-05-05 | 2010-11-11 | Florida Renewable Energy Corporation | Fluid-based power generation system |
ES2736256T3 (es) | 2011-03-14 | 2019-12-27 | Drug Delivery Solutions Ltd | Composición oftálmica |
US9507157B2 (en) | 2014-12-17 | 2016-11-29 | Zhen Tang | Size-adjustable elliptical laser marker |
TWI713998B (zh) | 2019-02-22 | 2020-12-21 | 南亞塑膠工業股份有限公司 | 一種含二氧化鈦漿料的製作及應用於回收聚酯纖維 |
-
1998
- 1998-07-08 US US09/111,681 patent/US6417168B1/en not_active Expired - Lifetime
-
1999
- 1999-03-04 DK DK99908641T patent/DK1058562T3/da active
- 1999-03-04 CA CA002322592A patent/CA2322592A1/en not_active Expired - Lifetime
- 1999-03-04 AU AU28021/99A patent/AU757237C/en not_active Expired
- 1999-03-04 AT AT99908641T patent/ATE334702T1/de active
- 1999-03-04 EP EP99908641A patent/EP1058562B1/en not_active Revoked
- 1999-03-04 DE DE69932600T patent/DE69932600T2/de not_active Expired - Lifetime
- 1999-03-04 JP JP2000534245A patent/JP2002505309A/ja active Pending
- 1999-03-04 WO PCT/US1999/004777 patent/WO1999044645A1/en active IP Right Grant
- 1999-03-04 EP EP15183218.5A patent/EP3034093B1/en not_active Revoked
- 1999-03-04 PT PT99908641T patent/PT1058562E/pt unknown
- 1999-03-04 ES ES99908641T patent/ES2270586T3/es not_active Expired - Lifetime
- 1999-03-04 ES ES06076149.1T patent/ES2551932T3/es not_active Expired - Lifetime
-
2002
- 2002-03-19 US US10/100,952 patent/US7625558B2/en not_active Expired - Lifetime
-
2006
- 2006-09-14 CY CY20061101312T patent/CY1105475T1/el unknown
-
2008
- 2008-05-02 US US12/114,475 patent/US20090010935A1/en not_active Abandoned
-
2011
- 2011-04-05 US US13/080,313 patent/US20120014965A1/en not_active Abandoned
- 2011-10-11 JP JP2011224347A patent/JP5719270B2/ja not_active Expired - Lifetime
-
2013
- 2013-03-12 US US13/796,468 patent/US20130204069A1/en not_active Abandoned
-
2014
- 2014-09-12 US US14/485,525 patent/US20150010551A1/en not_active Abandoned
-
2015
- 2015-06-03 US US14/729,798 patent/US20160289334A2/en not_active Abandoned
-
2016
- 2016-12-21 HK HK16114528A patent/HK1225997A1/zh unknown
-
2017
- 2017-02-01 US US15/422,046 patent/US20170355778A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HK1225997A1 (zh) | 2017-09-22 |
AU2802199A (en) | 1999-09-20 |
US20160289334A2 (en) | 2016-10-06 |
US20020165193A1 (en) | 2002-11-07 |
US20120014965A1 (en) | 2012-01-19 |
US20090010935A1 (en) | 2009-01-08 |
AU757237C (en) | 2004-03-18 |
US20150010551A1 (en) | 2015-01-08 |
EP3034093B1 (en) | 2019-03-13 |
PT1058562E (pt) | 2006-11-30 |
CY1105475T1 (el) | 2010-04-28 |
US6417168B1 (en) | 2002-07-09 |
JP2002505309A (ja) | 2002-02-19 |
AU757237B2 (en) | 2003-02-06 |
EP1058562B1 (en) | 2006-08-02 |
CA2322592A1 (en) | 1999-09-10 |
DE69932600T2 (de) | 2007-08-09 |
EP1058562A1 (en) | 2000-12-13 |
US20160083478A1 (en) | 2016-03-24 |
ES2270586T3 (es) | 2007-04-01 |
EP3034093A1 (en) | 2016-06-22 |
ES2551932T3 (es) | 2015-11-24 |
US20130204069A1 (en) | 2013-08-08 |
US7625558B2 (en) | 2009-12-01 |
ATE334702T1 (de) | 2006-08-15 |
JP5719270B2 (ja) | 2015-05-13 |
JP2012017341A (ja) | 2012-01-26 |
DE69932600D1 (de) | 2006-09-14 |
WO1999044645A1 (en) | 1999-09-10 |
EP1058562A4 (en) | 2003-02-05 |
US20170355778A1 (en) | 2017-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1058562T3 (da) | Præparater og fremgangsmåder til behandling af tumorer | |
ATE186219T1 (de) | Kombination von antihormonale und bindende moleküle zur krebsbehandlung | |
ATE113295T1 (de) | Tumornekrosefaktor, verfahren zu seiner herstellung, denselben enthaltende zusammensetzungen, dafür kodierende dns und diese dns verwendendes testverfahren. | |
DE60129695D1 (de) | Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme | |
ID26620A (id) | Penghambatan kinase raf yang menggunakan urea-urea heterosiklik yang disubstitusi | |
DK0957903T3 (da) | Norbornen- og norbornandiolforbindelser til behandling af pigmenteringslidelser, neurodegenerative sygdomme eller proliferative hudlidelser | |
ATE407949T1 (de) | Charakterisierung der proteinfamilie von soc/crac kalziumkanälen | |
ATE550042T1 (de) | Behandlung von krebs mithilfe cytokin- exprimierender polynukleotide und zusammensetzungen dafür | |
DE60027768D1 (de) | Behandlung von metastatischer krankheit | |
NO20070951L (no) | Inhibitorer av angiopoientinlignende-4-protein, kombinasjoner og deres anvendelse. | |
DE1019040T1 (de) | Hemmung von p38 kinase aktivität durch arylharnstoff | |
ATE194383T1 (de) | Antisense oligonukleotide gegen die alpha- regulatorische untereinheit der camp-abhängigen protein-kinase zur behandlung von krebs | |
DK0512528T3 (da) | Farmaceutisk præparat omfattende et cytokin | |
ATE344670T1 (de) | Synergistische kombination zur behandlung von kolorektalkarzinom | |
DK2182064T3 (da) | Gen udtrykt i prostatakræft | |
DE69940980D1 (de) | Rana pipiens proteine und deren verwendung in der behandlung von tumoren | |
NO991161L (no) | TNF-<beta>-lignende protein for behandling av prostatacancer, og beslektede nukleinsyremolekyler, farmas°ytiske sammensetninger og metoder | |
DK1315519T3 (da) | Farmaceutiske sammensætninger og fremgangsmåder, der kan anvendes til behandling af cancer eller leverfibrose | |
EP1745799A3 (en) | Compositions and methods of treating tumors | |
ATE403716T1 (de) | Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen | |
ATE100319T1 (de) | Verwendung von chinolyl-und isochinolyloxazol-2- onen zur herstellung eines arzneinmittels zur behandlung von gegen eine vielzahl von arzneimitteln resistenten tumoren. | |
DE500713T1 (de) | Derivate des 3,3,5-trimethylcyclohexylesters von 2-methylpropionsaeure, ihr herstellungsverfahren sowie diese enthaltende therapeutische kompositionen. |